MPDD – Revolutionary Pain Management Device – FDA 510k Cleared
Americans spend over $85 billion dollars annually on treatment for chronic back pain. Much of this money is wasted on failed surgeries and misdiagnosis. In fact, the medical industry has a term for this; “FBSS” or Failed Back Surgery Syndrome. Medicare is charged billions of dollars annually for these failures. Both Physicians and Medicare are desperately in need of a better diagnosis tool for chronic back pain and muscular pain. The MPDD device is a developed clinical and technological platform that promises to greatly increase the accuracy with which muscle pain is diagnosed and drive down health care costs associated with chronic pain. EPGL Med has set forth to capitalized on an opportunity to work with leading pain management physicians, on marketing a medical device to facilitate a revolutionary method for pain diagnosis. The MPDD has received FDA 510K clearance for marketing and manufacture.
The combined national and international market for the MPDD device is estimated at $4.5 billion dollars annually in device sales and recurrent education and training revenues. The primary market will be pain management physicians and primary care physicians. This market will then expand to sports medicine and physical therapists. Ideally the DHS MPDD device will be as common as the stethoscope in a physician’s hand. Signaling a new era in pain diagnosis where the idea of chronic muscle pain will be virtually nonexistent.
The MPDD does not compete with current methods of pain diagnosis. Instead, MPDD will enhance current methods of diagnosis and treatment. Thus, helping realize the full value of current diagnostic tools such as MRI, CT scan, X-ray standard physical examination.
MPDD will compliment the pharmaceutical industry by helping doctors to properly correlate the prescription of painkillers to the correct source of pain. This may help patients achieve lasting relief by pharmaceutics alone, rather than more drastic procedures such as surgery.
MPDD incorporates two technologies, one of clinical methodology and one for device technology, for a combined diagnostic package that allows for a revolution in the accuracy and precision of muscle pain diagnosis. The first is a diagnostic method developed over 50 years by a series of key opinion leaders in pain management. The patented version of this methodology allows for the diagnosis of muscles in a dynamic, natural, state (as opposed to static). This simple feature greatly increases the precision of the diagnosis while the unique methodology provides isolation of the pain generator, increasing accuracy. The MPDD device incorporates leading edge technology for trans-cutaneous-electroneural stimulation, a safe, effective and proven way of stimulating muscle. The patented method and the MPDD device are inherently linked, a powerful innovation in the management of chronic pain.
